Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

about

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

Item

http://www.wikidata.org/entity/Q44318431

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@en

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@nl

type

Item

label

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@en

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@nl

prefLabel

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@en

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@nl

P1476

Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.

@en

P2093

Chengkon Shih

http://www.w3.org/2001/XMLSchema#string

Chongtie Shi

http://www.w3.org/2001/XMLSchema#string

Feng Wang

http://www.w3.org/2001/XMLSchema#string

Genyan Zhang

http://www.w3.org/2001/XMLSchema#string

Jiakui Li

http://www.w3.org/2001/XMLSchema#string

Jin Wang

http://www.w3.org/2001/XMLSchema#string

Song You

http://www.w3.org/2001/XMLSchema#string

Xinyu Li

http://www.w3.org/2001/XMLSchema#string

Yan Zhou

http://www.w3.org/2001/XMLSchema#string

Yanwei Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Mutational landscape and significance across 12 major cancer types

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

PI3K pathway alterations in cancer: variations on a theme

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.

Everolimus for advanced pancreatic neuroendocrine tumors.

Big opportunities for small molecules in immuno-oncology.

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

P304

5077-5087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S142492

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29118584

http://www.w3.org/2001/XMLSchema#string

P932

5659256

http://www.w3.org/2001/XMLSchema#string